Drug intelligence / Profile preview

siRNA targeting uc.110

Development stage: Preclinical
Lead developer: University of Virginia
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Parenteral

Overview

siRNA targeting uc.110 is an experimental RNA interference (RNAi) therapeutic designed to silence the expression of the transcribed ultra-conserved region (TUCR) uc.110. uc.110 is a long non-coding RNA (lncRNA) that is significantly upregulated in gliomas, particularly glioblastoma (GBM). Research conducted at the University of Virginia has characterized uc.110 as an oncogene that promotes tumor cell viability, accumulation, and invasion. In preclinical studies, siRNA-mediated knockdown of uc.110 resulted in reduced tumor volume and improved overall survival in animal models, highlighting its potential as a novel therapeutic target for malignant brain tumors.

Other names: uc.110 siRNAsi-uc.110

Targets

TUC110 (Transcribed ultra-conserved region 110 RNA)

Beyond the preview

Go deeper on siRNA targeting uc.110.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on siRNA targeting uc.110.

Explore the full profile